Hostname: page-component-848d4c4894-sjtt6 Total loading time: 0 Render date: 2024-06-26T21:09:51.813Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical observation of 11 patients under clozapine-lithium association

Published online by Cambridge University Press:  16 April 2020

C Bryois  and
F Ferrero
C Bryois
Affiliation:
Clinique psychiatrique universitaire, CH-1008Prilly, France
F Ferrero
Affiliation:
Clinique psychiatrique universitaire, CH-1008Prilly, France
Get access

Summary

Ten men and one woman aged 27 to 52 years and presenting chronic evolution of their psychotic disorders benefited from a treatment which associated lithium sulfate at a plasmatic level of 0.5 to 0.8 meq/L with clozapine (mean posology: 300 mg/day). Five patients presented chronic disorganized schizophrenia (295.14), five a schizoaffective disorder (295.70) and one patient chronic undifferentiated schizophrenia (295.94) according to DSM III-R. Nine of the eleven patients showed mood disorders in addition to their psychotic and dissociative symptomatology. The remaining two presented chronic disorganised schizophrenia with aggressive behaviour. The clozapine-lithium association led to stabilization and improvement in the condition of all patients. Nine patients are still undergoing treatment with satisfactory results. The mean duration of the clozapine-lithium treatment, which has proved to be well tolerated with regard to side-effects, is about five years.

Keywords

lithium-clozapine associationschizophreniamood disorder
Type
Short communication
Information
European Psychiatry , Volume 8 , Issue 4 , 1993 , pp. 213 - 218
Copyright
Copyright © Elsevier, Paris 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cohen, WJCohen, H (1974) Lithium carbonate, haloperidol and irreversible brain damage.JAMA 230, 1283–1287CrossRefGoogle ScholarPubMed
Johnson, NS (1980) Handbook of Lithium Therapy. MTP Press Ltd, Lancaster, 453CrossRefGoogle Scholar
Kane, JHonigfeld, GSinger, JMeltzer, H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45, 789–796CrossRefGoogle ScholarPubMed
Mc Elroy, SLDessain, ECPope, HGCole, JOKeck, PEFrankenberg, ERAizeley, HGO’Brien, S (1991) Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 52, 411–414Google Scholar
Pope, HG JRCole, JOChoras, PTFulwiler, GE (1986) Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 174, 493–495CrossRefGoogle ScholarPubMed
Shead, MH (1975) Lithium and the treatment of aggression. J Nerv Ment Dis 160, 108–118CrossRefGoogle Scholar
Shepherd, MWatt, DFalloon, ISmeeton, N (1989) The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med (Mono suppl) 15Google Scholar
Singh, SV (1982) Lithium carbonate/fluphenazine decanoate producing irreversible brain damage. Lancet ii, 1, 771Google Scholar
Spring, GK (1979) Neurotoxicity with combined use of lithium and thioridazine. J Clin Psychiatry 40, 135Google ScholarPubMed
Standisch — Barry HMAS, Shelly, MA (1983) Toxic neurological reaction to lithum and neuroleptics – a literature review. Hum Psychopharmacol 5, 275–280Google Scholar
Thomas, C (1979) Brain damage with lithium/haloperidol. Br H Psychiatry 134, 55Google ScholarPubMed
Von Knorring, L (1990) Possible mechanisms for presumed interaction between lithium and neuroleptics. Human Psychopharmacol 5, 287–292CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.